about
ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphomap130Cas mediates the transforming properties of the anaplastic lymphoma kinaseBRAF mutations in hairy-cell leukemiaOncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesNew and old functions of STAT3: a pivotal target for individualized treatment of cancerp27Kip1 repression of ErbB2-induced mammary tumor growth in transgenic mice involves Skp2 and Wnt/beta-catenin signalingThe anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation.Human rgr: transforming activity and alteration in T-cell malignancies.Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.The heterogeneous landscape of ALK negative ALCL.DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.Genetics of follicular lymphoma transformation.Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms.Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma.In vivo interference with Skp1 function leads to genetic instability and neoplastic transformationMicroscale Bioadhesive Hydrogel Arrays for Cell Engineering ApplicationsAmplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.STAT3: a multifaceted oncogene.Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cellsThe Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.S-phase kinase-associated protein 2 expression in non-Hodgkin's lymphoma inversely correlates with p27 expression and defines cells in S phaseThe Influence of Tissue Ischemia Time on RNA Integrity and Patient-Derived Xenografts (PDX) Engraftment Rate in a Non-Small Cell Lung Cancer (NSCLC) Biobank.CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell deathThe coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development.Patient-derived tumor xenografts of lymphoproliferative disorders: are they surrogates for the human disease?Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas.Comparative analysis of cancer vaccine settings for the selection of an effective protocol in miceThe anaplastic lymphoma kinase in the pathogenesis of cancer.Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.MicroRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphomaAnaplastic lymphoma kinase: an oncogene for tumor vaccination.Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma.The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitorsAnaplastic lymphoma kinase in human cancer.Anaplastic large-cell lymphoma.Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma.PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas.
P50
Q21129306-6F6015B2-9402-40EC-8C2E-1DE96261167DQ24315788-DB5F5AE6-AC17-47D6-83EE-EE8B92ACE57BQ24609980-00276E9F-D377-4DE8-89B0-82069E4FF14CQ26768158-06A19BD3-0A27-4D6A-87FF-951EAB6496C2Q28265930-8DCD534E-BD99-4389-8EFA-0B850A1FCB74Q28593729-0D1A68C7-30BA-469E-9B8E-08E99C63902DQ30484934-703804CE-0DD5-4818-9161-53E93733B3CCQ31098186-ACAC005C-754C-42CB-96CD-0FC2EBB742FFQ33415354-1CD0256B-18C2-453C-869F-B03F29528376Q33567012-381A3598-E9FE-429E-8FEF-62D7F8737734Q33804663-105C1583-8982-4203-A4EC-3BB256D3634EQ33910446-CF209F24-8E1D-49D0-8CB9-ACA42FDF9D1EQ34099059-C50A2572-3AFA-4F9A-A43E-70E367142614Q34284639-792BDA7C-0B66-423E-BC2C-7A6D9CC3F265Q34286428-DCAE8B46-6492-4F82-B143-91BBF0C821F1Q34334970-7BDBC528-FF99-4418-83A2-025F8CF38179Q34535370-9E05723A-8F1A-484E-8EB3-2EE69D95EFE4Q34657347-D8EADB24-4326-46D6-B558-BE94BBDDECDCQ34771828-999597DB-D65D-48B7-A0B8-60C429C0E06EQ35029454-A51A5BF3-539D-471A-B97E-AC9DFF6CCA21Q35218537-252FA3B5-878A-45DF-A214-397578D0B7A7Q35788983-349A46D1-406C-4D29-BE04-263D435D2B07Q35885771-5AB500A2-7296-4F5C-9EDC-980F3E7B34D3Q35930211-75611224-1707-447E-A98B-A9027F8259F9Q36193517-88250A44-95DB-4823-8DE8-19B5B482DD7DQ36395729-6AD40C49-ACFF-41DE-AE10-AFB59718C317Q36596874-BB2503D2-DBC5-42C7-B388-85E342C256B8Q36859227-86993F6C-ACC0-4BE5-8AC1-948613511E3AQ37039605-0A671A10-9BBC-4A7C-AD37-1FBFEEFA82EEQ37164915-208AE3F5-9D17-462B-A8EE-AEAA67E18DA1Q37186470-0BB9BA31-FB70-465B-A96A-683E391B15D0Q37426387-0F432C74-E1AC-46FB-A4A8-0B220BAA0036Q37439553-D9176AF4-3669-4B31-B6D8-8D38E621BB65Q37520396-8F21E68F-0572-4E07-84E8-ADC13458002CQ37526352-5314310A-0286-43A6-BDBD-5FAA57890B13Q37622508-09E83FF5-F885-47BF-B132-EFB5027A0FDAQ37866541-16501DF9-DA0B-412B-BEAB-06CB026AAF62Q37919489-3B4972CE-B3D2-4BBB-B177-7E8147AEFCFAQ38106810-08EF5423-30C8-49B9-AAD2-42165512B28DQ38239219-37B7B1DF-1CA1-4433-826A-9FE7F294B015
P50
description
onderzoeker
@nl
name
Giorgio Inghirami
@ast
Giorgio Inghirami
@en
Giorgio Inghirami
@es
Giorgio Inghirami
@nl
Giorgio Inghirami
@sl
type
label
Giorgio Inghirami
@ast
Giorgio Inghirami
@en
Giorgio Inghirami
@es
Giorgio Inghirami
@nl
Giorgio Inghirami
@sl
prefLabel
Giorgio Inghirami
@ast
Giorgio Inghirami
@en
Giorgio Inghirami
@es
Giorgio Inghirami
@nl
Giorgio Inghirami
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z